# Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

> **NCT07298200** · PHASE1 · RECRUITING · sponsor: **Jia Wei** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** XH001 Injection
- **DRUG:** Tumor vaccine-induced specific T-cell injection

## Key facts

- **NCT ID:** NCT07298200
- **Lead sponsor:** Jia Wei
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-26
- **Primary completion:** 2028-06
- **Final completion:** 2029-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298200, "Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07298200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*